Intercept is a biopharmaceutical company focused on building a healthier tomorrow for people with progressive non-viral liver diseases.

The 2023 Intercept Educational Grants program is for U.S. organizations only and will begin accepting grant proposals November 17, 2022.

Healthcare Professional Education:

  • Information needed for submittal of 2023 Educational Grants:
  • Education Grants may be awarded to accredited education providers and/or independent third-party Healthcare Education companies that develop and administer programs designed to meet the education needs of healthcare professionals including physicians, nurse practitioners, physician assistants, pharmacists, nurses, and research scientists or others working in the fields of Hepatology and/or Gastroenterology
  • Grant recipients are responsible for the content, quality, scientific integrity, and adherence to ACCME Standards for Commercial Support of all activities they certify for accreditation


Primary Biliary Cholangitis (PBC), depending on educational needs assessment(s):

  • Importance of routinely/closely monitoring a broad range of biochemical and other types of markers to further aid the development of appropriate patient care pathways
  • Importance of the appropriate and timely initiation of second-line treatment
  • Real-world evidence related to PBC natural history, diagnosis, disease management, and the effect of approved and emerging second-line therapies on clinical outcomes

Non-Alcoholic Steatohepatitis (NASH), depending on educational needs assessment(s):

  • Importance of timely identification and management of patients with advanced fibrosis without cirrhosis, who are at greatest risk of progression to cirrhosis and associated negative clinical outcomes
  • Evolving non-invasive approaches related to the detection and diagnosis of NASH as well as identification and monitoring of liver fibrosis due to NASH
  • Real-world evidence related to natural history, burden/cost of illness, diagnosis, disease management and clinical outcomes of advanced fibrosis due to NASH, including the effect of approved and emerging therapies
  • Evolving Models of Care, Linkages to Care, and/or Care Coordination efforts that highlight innovative care management approaches for patients with liver fibrosis due to NASH

Healthcare Inequities in PBC and NASH, depending on educational needs assessment(s):

  • Description and investigation of potential barriers and disparities impacting timely diagnosis of PBC and NASH
  • Evaluation of potentially relevant differences in monitoring & treatment across populations 
  • Examination of potentially relevant differences in PBC- and/or NASH-related outcomes (short- and/or long-term) across disparate populations

Program Parameters to consider for 2023 applications:

  • Intercept is currently prioritizing national and virtual programs with enduring Certified Medical Education material(s)
  • Advanced practice provider inclusion is encouraged
  • 2-year education certification is preferred
  • All grant proposals should incorporate plans to measure learner progress with a Moore’s rating of ≥ 4
  • Please ensure your educational grant proposal is submitted a minimum of 90 days prior to commencement of the activity.